Mariner Investment Group LLC held its position in Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) during the second quarter, Holdings Channel reports. The firm owned 63,090 shares of the biopharmaceutical company’s stock at the end of the second quarter. Mariner Investment Group LLC’s holdings in Merrimack Pharmaceuticals were worth $340,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company.
Legal & General Group Plc boosted its position in Merrimack Pharmaceuticals by 40.6% in the first quarter. Legal & General Group Plc now owns 26,766 shares of the biopharmaceutical company’s stock valued at $226,000 after buying an additional 7,732 shares during the period. Chicago Equity Partners LLC boosted its position in Merrimack Pharmaceuticals by 2.5% in the second quarter.
Chicago Equity Partners LLC now owns 48,180 shares of the biopharmaceutical company’s stock valued at $260,000 after buying an additional 1,160 shares during the period. Commonwealth Equity Services Inc boosted its position in Merrimack Pharmaceuticals by 1.9% in the first quarter.
Commonwealth Equity Services Inc now owns 35,881 shares of the biopharmaceutical company’s stock valued at $300,000 after buying an additional 665 shares during the period. Boston Advisors LLC purchased a new position in Merrimack Pharmaceuticals during the second quarter valued at $311,000.
Finally, BlackRock Group LTD boosted its position in Merrimack Pharmaceuticals by 44.5% in the first quarter. BlackRock Group LTD now owns 44,007 shares of the biopharmaceutical company’s stock valued at $369,000 after buying an additional 13,542 shares during the period.
Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) traded up 2.62% on Wednesday, reaching $5.87. 1,476,983 shares of the company’s stock were exchanged. The company’s market cap is $749.75 million. Merrimack Pharmaceuticals Inc. has a 52-week low of $5.02 and a 52-week high of $11.18. The firm’s 50 day moving average price is $5.69 and its 200 day moving average price is $6.59.
Several research analysts recently weighed in on the stock. Zacks Investment Research cut shares of Merrimack Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 19th.
Cowen and Company restated a “buy” rating on shares of Merrimack Pharmaceuticals in a report on Tuesday, May 3rd. Brean Capital restated a “buy” rating and set a $16.00 price target on shares of Merrimack Pharmaceuticals in a report on Friday, May 20th.
Robert W. Baird initiated coverage on shares of Merrimack Pharmaceuticals in a research note on Thursday, May 26th. They issued a “neutral” rating and a $8.00 target price on the stock. Finally, Mizuho reiterated a “buy” rating and issued a $13.00 target price on shares of Merrimack Pharmaceuticals in a research note on Friday, May 20th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Merrimack Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $12.54.
